EU pays 336 million euros for doses of AstraZeneca's potential COVID-19 vaccine

EU pays 336 million euros for doses of AstraZeneca's potential COVID-19 vaccine The European Commission has paid 336 million euros ($396 million) to secure at least 300 million doses of the potential COVID-1 vaccine being developed by British drug maker AstraZeneca , a spokesman said on Thursday. Reuters Editorial U.S.

BRUSSELS (Reuters) - The European Commission has paid 336 million euros ($396 million) to secure at least 300 million doses of the potential COVID-1 vaccine being developed by British drug maker AstraZeneca (AZN.L), a spokesman said on Thursday.

Brussels signed the deal on behalf of EU states for the supply of at least 300 million doses of its COVID-19 vaccine candidate. It has an option for a further 100 million, the spokesman said.

“We cannot indicate at this stage the specific pricing per dose. However, a significant part of the overall costs are funded by a contribution from the overall ESI funding for vaccines,” he said, referring to the bloc’s so-called emergency support instrument.